Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2020; 11(12):3685-3692. doi:10.7150/jca.43966 This issue Cite

Research Paper

A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model

Jiaqi Huang1,2, Di Zhang1,2, Yu Bai3, Pamela Yang3, Ligang Xing1,2✉, Jinming Yu1,2✉

1. Department of Clinical Medicine, Shandong University, Jinan, Shandong 250000, P.R. China.
2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China.
3. Dizal (Jiangsu) Pharmaceutical Co., Ltd., Wuxi, Jiangsu 214028, P.R. China.

✉ Corresponding authors: Dr Ligang Xing, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, Shandong 250117, P.R. China, E-mail: More

Citation:
Huang J, Zhang D, Bai Y, Yang P, Xing L, Yu J. A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. J Cancer 2020; 11(12):3685-3692. doi:10.7150/jca.43966. https://www.jcancer.org/v11p3685.htm
Other styles

File import instruction

Abstract

Accumulated extracellular adenosine suppresses antitumor immunity via adenosine 2A receptor (A2AR). Blockade of A2AR with DZD2269 can inhibit phosphorylation of cAMP response element-binding protein mediated by adenosine analogue in vitro and in vivo. Irradiation can cause the release of adenosine and lead to a rapid increase in free extracellular adenosine in the tumour area. DZD2269, a novel A2AR Antagonism, induces incomplete antitumor responses in multiple syngeneic mouse tumour models. Combining DZD2269 with IR can induce a synergistic anticancer effect. IR increases the infiltration of various subtypes of T cells, including CD4+, CD8+ and Foxp3+ T cells, into the tumour area. Combining IR and DZD2269 improves the tumour immune microenvironment, leading to suppressed infiltration of regulatory T (Treg) cells and enhanced IFN-γ expression by tumour-infiltrating lymphocytes. The results support the use of A2AR antagonism with DZD2269 as a therapeutic strategy for monotherapy or combination therapy with IR.

Keywords: adenosine, A2AR, irradiation, immunotherapy

Citation styles

APA
Huang, J., Zhang, D., Bai, Y., Yang, P., Xing, L., Yu, J. (2020). A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. Journal of Cancer, 11(12), 3685-3692. https://doi.org/10.7150/jca.43966.

ACS
Huang, J.; Zhang, D.; Bai, Y.; Yang, P.; Xing, L.; Yu, J. A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. J. Cancer 2020, 11 (12), 3685-3692. DOI: 10.7150/jca.43966.

NLM
Huang J, Zhang D, Bai Y, Yang P, Xing L, Yu J. A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. J Cancer 2020; 11(12):3685-3692. doi:10.7150/jca.43966. https://www.jcancer.org/v11p3685.htm

CSE
Huang J, Zhang D, Bai Y, Yang P, Xing L, Yu J. 2020. A2AR Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. J Cancer. 11(12):3685-3692.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use